Early progenitor cells from human mobilized peripheral blood express low levels of the flt3 receptor, but exhibit various biological responses to flt3-L
- 1 August 1999
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 106 (2) , 357-367
- https://doi.org/10.1046/j.1365-2141.1999.01582.x
Abstract
The biological effects of flt3‐L, and the expression of its tyrosine kinase receptor (flt3, CD135) were investigated on the immature subsets of human circulating peripheral blood progenitors obtained from cancer patients or normal volunteer donors, after mobilization with rhG‐CSF or chemotherapy. flt3 was expressed at low levels, and its expression increased concomitantly with expression of CD38 within the CD34+ cell population. Despite this low‐level expression, flt3‐L exerted synergistic effects with a combination of c‐kit ligand, IL‐3, IL‐6, GM‐CSF and G‐CSF, mainly to induce proliferation of CD34+/CD38− cells. In addition, flt3‐L increased the detection of HPP‐CFC, both immediately after cell selection, and after 7 and 14 d of cultures. We conclude that flt3‐L is active on circulating early mobilized haemopoietic progenitors, despite the low‐ level expression of its receptor.Keywords
This publication has 43 references indexed in Scilit:
- Blood and marrow transplantation activity in Europe 1996Bone Marrow Transplantation, 1998
- CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimensBone Marrow Transplantation, 1997
- The Effects of Flk-2/flt3 Ligand as Compared with c-kit Ligand on Short-Term and Long-Term Proliferation of CD34+ Hematopoietic Progenitors Elicited from Human Fetal Liver, Umbilical Cord Blood, Bone Marrow, and Mobilized Peripheral BloodJournal of Hematotherapy, 1996
- Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.The Journal of Experimental Medicine, 1996
- Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitorsImmunity, 1995
- The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors.The Journal of Experimental Medicine, 1995
- Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activationCell, 1995
- Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAsNature, 1994
- Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cellsCell, 1993
- A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populationsCell, 1991